Rafferty Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-82,757
| Closed | -$2.6M | – | 1127 |
|
|
2026
Q2 | $2.6M | Sell |
82,757
-37,975
| -31% | -$1.12M | 0.01% | 579 |
|
|
2026
Q1 | $2.99M | Sell |
120,732
-34,304
| -22% | -$817K | 0.01% | 516 |
|
|
2025
Q4 | $3.62M | Sell |
155,036
-2,008
| -1% | -$44.7K | 0.01% | 519 |
|
|
2025
Q3 | $3.09M | Buy |
157,044
+61,328
| +64% | +$1.26M | 0.01% | 543 |
|
|
2025
Q2 | $2.08M | Sell |
95,716
-8,983
| -9% | -$212K | 0.01% | 603 |
|
|
2025
Q1 | $2.54M | Sell |
104,699
-12,393
| -11% | -$279K | 0.01% | 514 |
|
|
2024
Q4 | $2.44M | Sell |
117,092
-5,398
| -4% | -$116K | 0.01% | 586 |
|
|
2024
Q3 | $2.44M | Sell |
122,490
-63,004
| -34% | -$1.17M | 0.01% | 581 |
|
|
2024
Q2 | $2.87M | Sell |
185,494
-301,280
| -62% | -$4.69M | 0.01% | 540 |
|
|
2024
Q1 | $7.76M | Buy |
486,774
+134,612
| +38% | +$2.03M | 0.03% | 357 |
|
|
2023
Q4 | $5.92M | Sell |
352,162
-158,273
| -31% | -$2.16M | 0.03% | 404 |
|
|
2023
Q3 | $5.97M | Sell |
510,435
-204,440
| -29% | -$2.73M | 0.04% | 353 |
|
|
2023
Q2 | $9.6M | Buy |
714,875
+250,208
| +54% | +$3.6M | 0.05% | 218 |
|
|
2023
Q1 | $7.7M | Sell |
464,667
-27,784
| -6% | -$458K | 0.05% | 254 |
|
|
2022
Q4 | $9.16M | Buy |
492,451
+87,742
| +22% | +$1.35M | 0.08% | 200 |
|
|
2022
Q3 | $5.19M | Buy |
404,709
+218,609
| +117% | +$2.59M | 0.06% | 330 |
|
|
2022
Q2 | $1.3M | Sell |
186,100
-45,408
| -20% | -$333K | 0.01% | 570 |
|
|
2022
Q1 | $1.92M | Buy |
231,508
+2,920
| +1% | +$20.6K | 0.01% | 614 |
|
|
2021
Q4 | $1.55M | Buy |
228,588
+35,802
| +19% | +$235K | 0.01% | 746 |
|
|
2021
Q3 | $1.02M | Buy |
192,786
+594
| +0.3% | +$3.25K | 0.01% | 808 |
|
|
2021
Q2 | $1.1M | Sell |
192,192
-243,632
| -56% | -$1.26M | 0.01% | 846 |
|
|
2021
Q1 | $2.01M | Buy |
435,824
+375,238
| +619% | +$1.49M | 0.01% | 627 |
|
|
2020
Q4 | $202K | Sell |
60,586
-172,744
| -74% | -$580K | ﹤0.01% | 990 |
|
|
2020
Q3 | $693K | Buy |
233,330
+148,429
| +175% | +$580K | 0.01% | 633 |
|
|
2020
Q2 | $392K | Buy |
84,901
+50,853
| +149% | +$228K | 0.01% | 767 |
|
|
2020
Q1 | $131K | Sell |
34,048
-328,248
| -91% | -$1.35M | 0.01% | 550 |
|
|
2019
Q4 | $1.36M | Buy |
362,296
+192,878
| +114% | +$902K | 0.02% | 476 |
|
|
2019
Q3 | $900K | Buy |
+169,418
| New | +$903K | 0.01% | 565 |
|
Other funds holding CPRX
Rafferty Asset Management's CPRX Position: Q3 2026 in Review
Rafferty Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 82,757 shares — an estimated $2.6M sold.
Rafferty Asset Management first reported a position in CPRX in Q3 2019 and held it in 28 quarters. The position peaked at $9.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.
- Rafferty Asset Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- Rafferty Asset Management sold 82,757 Catalyst Pharmaceutical shares in Q3 2026, an estimated $2.6M.
- Rafferty Asset Management first reported a position in Catalyst Pharmaceutical in Q3 2019 and held it in 28 quarters.
- Rafferty Asset Management's Catalyst Pharmaceutical position peaked at $9.6M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.